drugset / Trial / NCT04024137

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

NCT04024137

Phase 2 Completed 172 enrolled Guangdong Raynovent Biotech Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the antiviral effect, as measured by the time to alleviation of influenza symptoms and viral titer in nasopharyngeal secretions in adults with acute uncomplicated influenza A following administration of ZSP1273.

Timeline

Start
2019-12-07
Primary completion
2020-05-18
Completion
2020-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Onradivir Small molecule 200 mg Oral
Subject Onradivir Small molecule 400 mg Oral
Subject Onradivir Small molecule 600 mg Oral

Indications